Scarica l'app Stockscreener
7.99
1.91%
0.15
Pre-mercato:
8.01
0.02
+0.25%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VTYX Giù?
Forum
Previsione
Precedente Chiudi:
$7.84
Aprire:
$7.83
Volume 24 ore:
2.07M
Relative Volume:
0.54
Capitalizzazione di mercato:
$570.16M
Reddito:
-
Utile/perdita netta:
$-192.96M
Rapporto P/E:
-2.4212
EPS:
-3.3
Flusso di cassa netto:
$-167.04M
1 W Prestazione:
-20.02%
1M Prestazione:
-1.24%
6M Prestazione:
+301.51%
1 anno Prestazione:
+207.31%
Intervallo 1D:
$7.60
$8.055
Intervallo di 1 settimana:
$7.60
$10.15
Portata 52W:
$0.783
$10.55
Ventyx Biosciences Inc Stock (VTYX) Company Profile
Nome
Ventyx Biosciences Inc
Settore
Industria
Telefono
(760) 407-6511
Indirizzo
12790 EL CAMINO REAL, SUITE 200, SAN DIEGO
Confronta VTYX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VTYX
Ventyx Biosciences Inc
|
7.99 | 559.45M | 0 | -192.96M | -167.04M | -3.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ventyx Biosciences Inc Stock (VTYX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-05 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-03-12 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2024-03-12 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-11-07 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-11-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-07 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-11-07 | Downgrade | Stifel | Buy → Hold |
| 2023-11-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-06-14 | Ripresa | Credit Suisse | Outperform |
| 2023-03-21 | Iniziato | Wells Fargo | Overweight |
| 2022-12-19 | Iniziato | Goldman | Buy |
| 2022-11-17 | Iniziato | Morgan Stanley | Overweight |
| 2022-09-07 | Iniziato | Stifel | Buy |
| 2022-09-01 | Iniziato | H.C. Wainwright | Buy |
| 2022-05-09 | Iniziato | Credit Suisse | Outperform |
| 2022-03-31 | Iniziato | Canaccord Genuity | Buy |
| 2022-02-01 | Iniziato | Oppenheimer | Outperform |
| 2021-11-15 | Iniziato | Jefferies | Buy |
| 2021-11-15 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Ventyx Biosciences Inc Borsa (VTYX) Ultime notizie
Ventyx Biosciences (NASDAQ:VTYX) Shares Gap DownShould You Sell? - MarketBeat
Ventyx Biosciences, Inc. $VTYX Shares Sold by Sio Capital Management LLC - MarketBeat
Ventyx Biosciences Announces Appointment to Advisory Board - marketscreener.com
Ventyx provides clinical and corporate updates - marketscreener.com
Ventyx Provides Clinical And Corporate Updates - TradingView
Ventyx Biosciences Expands Phase 2 Recurrent Pericarditis Study Into Canada, EU, UK - MarketScreener
Ventyx stock falls after delaying trial data to Q1 2026 By Investing.com - Investing.com Canada
Ventyx strengthens advisory board, expands phase 2 pericarditis study - Investing.com
Ventyx strengthens advisory board, expands phase 2 pericarditis study By Investing.com - Investing.com South Africa
Ventyx Provides Clinical and Corporate Updates - The Manila Times
Ventyx adds advisors and delays trial data to Q1 2026 - StreetInsider
Institutional owners may ignore Ventyx Biosciences, Inc.'s (NASDAQ:VTYX) recent US$77m market cap decline as longer-term profits stay in the green - simplywall.st
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Ventyx Biosciences, Inc. (VTYX) latest stock news and headlines - Yahoo Finance UK
Ventyx Biosciences to Participate in the Piper Sandler 37th Annual Healthcare Conference - GlobeNewswire
Reviewing Tharimmune (NASDAQ:THAR) and Ventyx Biosciences (NASDAQ:VTYX) - Defense World
Ventyx Biosciences (NASDAQ:VTYX) Reaches New 1-Year HighTime to Buy? - MarketBeat
With 57% ownership, Ventyx Biosciences, Inc. (NASDAQ:VTYX) boasts of strong institutional backing - Yahoo Finance
Ventyx Biosciences (VTYX) Outlook Strengthened by Cost Optimization and Positive Clinical Data - MSN
VTYX Stock Skyrockets 156% in a Month: Here's What You Need to Know - MSN
Will Ventyx Biosciences Inc. stock see insider buyingTrade Exit Summary & Weekly High Potential Stock Alerts - newser.com
Does Ventyx Biosciences Inc. stock trade at a discount to peersMarket Volume Report & Weekly High Return Forecasts - newser.com
Is Ventyx Biosciences Inc. stock attractive for growth ETFsJuly 2025 Trade Ideas & Daily Stock Momentum Reports - newser.com
How Ventyx Biosciences Inc. stock reacts to bond yieldsJuly 2025 Analyst Calls & Verified Momentum Stock Ideas - newser.com
Ventyx Biosciences (VTYX) Price Target Increased by 12.94% to 13.99 - MSN
Market reaction to Ventyx Biosciences Inc.’s recent newsGold Moves & Safe Capital Investment Plans - newser.com
Can Ventyx Biosciences Inc. stock double in next 5 years2025 Support & Resistance & Long-Term Growth Stock Strategies - newser.com
[Form 4] Ventyx Biosciences, Inc. Insider Trading Activity - Stock Titan
Is Ventyx Biosciences Inc. still worth holding after the dipStop Loss & Weekly High Potential Stock Alerts - newser.com
Will Ventyx Biosciences Inc. stock recover faster than peersEarnings Growth Report & Pattern Based Trade Signal System - newser.com
How Ventyx Biosciences Inc. stock performs during Fed tightening cycles2025 Pullback Review & AI Driven Stock Reports - newser.com
Ventyx Biosciences at Jefferies Conference: Strategic Focus on NLRP3 Inhibitors - Investing.com Canada
What high frequency data says about Ventyx Biosciences Inc.Quarterly Investment Review & Real-Time Buy Zone Alerts - newser.com
Why Ventyx Biosciences Inc. is moving todayJuly 2025 Rallies & Target Return Focused Stock Picks - newser.com
Ventyx Biosciences Inc Azioni (VTYX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.10%
1.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):